Stock 4579 RAQUALIA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company RaQualia Pharma Inc.

Equities

4579

JP3967150008

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-01 am EDT 		5-day change 1st Jan Change
604 JPY +1.51% Intraday chart for RaQualia Pharma Inc. -0.82% -12.21%
Mar. 26 RaQualia Pharma Inc. completed the acquisition of FIMECS, Inc. from Yusuke Tominari, Kamakanae, Nissay Capital No. 11 Investment Limited Partnership managed by Nissay Capital Co., Ltd., ANRI No. 4 Fund managed by ANRI and others. CI
Feb. 14 RaQualia Pharma Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2024 CI

Business Summary

RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

Number of employees: 67

Sales per Business

JPY in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
2,918 100.0 % 1,901 100.0 % -34.85%

Sales per region

JPY in Million2022Weight2023Weight Delta
United States
57.4 %
1,142 39.1 % 1,091 57.4 % -4.52%
Asia
42.1 %
1,034 35.4 % 801 42.1 % -22.55%
Japan
0.3 %
742 25.4 % 6 0.3 % -99.18%
Other
0.2 %
-- 4 0.2 % -

Managers

Managers TitleAgeSince
Hirofumi Takeuchi BRD
 Director/Board Member 52 13-12-31
Shuzo Watanabe BRD
 Director/Board Member 57 08-06-30

Members of the board

Members of the board TitleAgeSince
Michihiro Tsuchiya BRD
 Director/Board Member 76 20-03-25
Shuzo Watanabe BRD
 Director/Board Member 57 08-06-30
Yuichi Kakinuma BRD
 Director/Board Member 46 21-03-24
Hirofumi Takeuchi BRD
 Director/Board Member 52 13-12-31
Kosuke Ishii BRD
 Director/Board Member 41 21-03-24
Megumi Uzu BRD
 Director/Board Member 63 21-03-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 21,638,281 17,020,130 ( 78.66 %) 51 ( 0.000236 %) 78.66 %

Shareholders

NameEquities%Valuation
Yuichi Kakinuma
11.03 %
2,384,700 11.03 % 10 M ¥
PFIZER, INC.
3.436 %
743,000 3.436 % 3 M ¥
Heights Capital Management, Inc.
2.890 %
625,000 2.890 % 3 M ¥
ADVANCED MEDIA, INC.
1.035 %
223,800 1.035 % 913 863 ¥
Raqualia Pharma Restricted Stock Compensation Plan
0.1278 %
27,637 0.1278 % 112 853 ¥
DFA Australia Ltd.
0.007973 %
1,724 0.007973 % 7 040 ¥
Simplex Asset Management Co., Ltd.
0.000000 %
0 0.000000 % - ¥

Holdings

NameEquities%Valuation
ADVANCED MEDIA, INC.
1.36%
 250,800 1.36% 2,730,969 $
ELANCO ANIMAL HEALTH INCORPORATED
0.00%
 15,267 0.00% 248,547 $

Company contact information

RaQualia Pharma, Inc.

Meieki Southside Square, 8/F 1-21-19 Meikei Minami

450-0003, Nagoya

+

http://www.raqualia.co.jp
address RaQualia Pharma Inc.(4579)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
595 JPY
Average target price
1,800 JPY
Spread / Average Target
+202.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
RAQUALIA PHARMA INC. Stock RaQualia Pharma Inc.
-12.21% 81.71M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.96% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.86% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4579 Stock
  4. Company RaQualia Pharma Inc.